Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Risk Factors for Venous Thromboembolism
2003 Standout
Antithrombin III I. Evaluation of an automated antithrombin III method
1978
Heparin-Protein Interactions
2002 Standout
Inflammation and Alzheimer's disease
2000 Standout
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
2001 StandoutNature
Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis
2002
Intracellular degradation of secretion defect‐type mutants of antithrombin is inhibited by proteasomal inhibitors
1997 StandoutNobel
Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets
1990
Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.
1987
Antithrombin Cambridge, 384 Ala to Pro: A new variant identified using the polymerase chain reaction
1989
Congenital antithrombin III deficiency
1989
Double-blind, Placebo-controlled Trial of Antithrombin III Concentrates in Septic Shock With Disseminated Intravascular Coagulation
1993
The anticardiolipin antibody in elderly stroke patients: its effects on stroke types, recurrence, and the coagulation-fibrinolysis system
2009
The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women
1995 Standout
Omega-3 fatty acids in health and disease and in growth and development
1991 Standout
Recurrence of venous thromboembolism in patients with familial thrombophilia
1997
Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans
1990
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
1995 Standout
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
1995 Standout
Heparin cofactor II in adults and infants with thrombosis and DIC
1989
Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation
1992
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Diabetes and Atherosclerosis
2002 Standout
Thrombin generation after physical exercise
1993
Resistance to Activated Protein C as a Basis for Venous Thrombosis
1994 Standout
Prevention of Venous Thromboembolism
2004 Standout
Antithrombin Cambridge II, 384 Ala to Ser Further evidence of the role of the reactive centre loop in the inhibitory function of the serpins
1991
Ventilator-Induced Lung Injury
2013 Standout
Prevention of Venous Thromboembolism
2008 Standout
Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases
1998
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
2001 Standout
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
1991 Standout
World distribution of factor V Leiden
1995 Standout
Disseminated Intravascular Coagulation
1999 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis
1991
Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor‐1 mRNA in cultured human endothelial cells
1995 StandoutNobel
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
1989
Application of the Open-Lung Concept during Positive-Pressure Ventilation Reduces Pulmonary Inflammation in Newborn Piglets
2003
Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects
1993
Protease nexin I immunostaining in alzheimer's disease
1989
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Homocysteine and Atherothrombosis
1998 Standout
Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle
2013 StandoutNobel
Effects of human soluble thrombomodulin on experimental glomerulonephritis
2002 StandoutNobel
The immunopathogenesis of sepsis
2002 StandoutNature
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
1987 Standout
Development of the human coagulation system in the full-term infant
1987 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Inherited thrombophilia: pathogenesis, clinical syndromes, and management [see comments]
1996
Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction
1985
Maturation of the hemostatic system during childhood
1992 Standout
The Mutation Ala677→Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis
1997
Biologic Effects of Transdermal Estradiol
1986
Serpin Structure, Mechanism, and Function
2002 Standout
Role of external Na+ and cytosolic pH in agonist-evoked cytosolic Ca2+ response in human platelets
1994
Hypercoagulability and thrombosis
1994
Antithrombin III Deficiency and Thromboembolism
1981
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.
1987 Standout
The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities
1984
Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity
1988
Metabolic changes during the normal menstrual cycle: A longitudinal study
1990
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
1987
DNA sequences of structural genes for Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
1996 Standout
DNA determinants important in sequence recognition by Eco RI endonuclease.
1981 StandoutNobel
The Effect of Progesterone on the Haemostatic Mechanism
1997
DEFICIENCIES OF PROTEIN C, AN INHIBITOR OF BLOOD COAGULATION
1982
Neonatal antithrombin III
1984
Treatment of congenital antithrombin III deficiency with concentrates
1982
Inhibition of the hydrolytic activity of thrombin by chitin heparinoids
1986
The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator
1990 StandoutNobel
Deep Vein Thrombosis After Hip Surgery Among Thai
1988
The Size and Shape of Human and Bovine Antithrombin III
1977
The covalent nature of the human antithrombin III–thrombin bond
1980
Partial NH2- and cooh-terminal sequence analyses of Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
2000
Hemostasis and thromboembolism in children with nephrotic syndrome: Differences from adults
1987
Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome
2000 Standout
Epidemiology of coagulation disorders
1992
Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase
1982
Aortocoronary Saphenous Vein Graft Disease
1998 Standout
A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation.
1980
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
1986
The Epidemiology of Venous Thromboembolism
2003 Standout
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia
1984
Coronary Plaque Disruption
1995 Standout
Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp)
1994
Hereditary Protein S Deficiency: Clinical Manifestations
1987
Development of Large Scale Fractionation Methods
1979
Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin
1976
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
The Effect of N-6 and N-3 Polyunsaturated Fatty Acids on Hemostasis, Blood Lipids and Blood Pressure
1983
Venous thrombosis: a multicausal disease
1999 Standout
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
1988
Haemostatic Factors and Inhibitors and Coronary Artery Bypass Grafting: Preoperative Alterations and Relations to Graft Occlusion
1994
Chitosan Chemistry and Pharmaceutical Perspectives
2004 Standout
Effects of Recombinant Human Soluble Thrombomodulin (rhs-TM) on a Rat Model of Disseminated Intravascular Coagulation with Decreased Levels of Plasma Antithrombin III
1994
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
1987 Standout
The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue.
1980
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
1983
Partial NH2- and COOH-terminal sequence and cyanogen bromide peptide analysis of Escherichia coli sn-glycerol-3-phosphate acyltransferase.
1983 StandoutNobel
Works of O.R. Ødegård being referenced
Heparin cofactor activity measured with an amidolytic method
1975
A Simple Amidolytic Method for the Determination of Functionally Active Antithrombin III
1976
Antifactor Xa Activity Measured with Amidolytic Methods
1976
Evaluation of an amidolytic heparin cofactor assay method
1975
Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)
1977
Antithrombin III: Critical Review of Assay Methods. Significance of Variations in Health and Disease
1977
A Simple Amidolytic Method for the Determination of Functionally Active Antithrombin III
1976
On Use of Chromogenic Substrates for Studies of Coagulation Inhibitors
1978
Heparin Cofactor Activity and Antithrombin III Concentration in Plasma Related to Age and Sex
1976
Antifactor Xa Activity in Thrombophilia Studies in a Family with At‐III Deficiency
1977
Antithrombin III: Critical Review of Assay Methods
1978
Simultaneous inactivation of thrombin and factor Xa by AT-III: Influence of heparin
1978